Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Peg-interferon Alpha-2a in Myelofibrosis
NCT02742324Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Mar 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib and peginterferon alfa-2a in myelofibrosis (MF), sponsored by French Innovative Leukemia Organisation. Started Mar 2016; status: completed.
02
Drugs
ruxolitinibpeginterferon alfa-2a
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02742324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742324.